The β3 adrenoceptor in proliferative retinopathies: "Cinderella" steps out of its family shadow.

[1]  S. Pujadas,et al.  β3 adrenergic agonist treatment in chronic pulmonary hypertension associated with heart failure (SPHERE‐HF): a double blind, placebo‐controlled, randomized clinical trial , 2022, European journal of heart failure.

[2]  M. C. Michel.  Are β3‐adrenoceptor gene polymorphisms relevant for urology? , 2022, Neurourology and urodynamics.

[3]  Dawei Song,et al.  Application and mechanism of anti-VEGF drugs in age-related macular degeneration , 2022, Frontiers in Bioengineering and Biotechnology.

[4]  Y. Shao,et al.  Progress and Challenges of Anti-VEGF Agents and Their Sustained-Release Strategies for Retinal Angiogenesis , 2022, Drug design, development and therapy.

[5]  C. Lagrasta,et al.  Β-blockers activate autophagy on infantile hemangioma-derived endothelial cells in vitro. , 2022, Vascular pharmacology.

[6]  C. Deng,et al.  Association Between Trp64Arg Polymorphism of Beta-3 Adrenergic Receptor Gene and Susceptibility to Overactive Bladder: A Meta-Analysis , 2022, Frontiers in Genetics.

[7]  H. Bundgaard,et al.  Hemodynamic Effects of Cyclic Guanosine Monophosphate-Dependent Signaling Through β3 Adrenoceptor Stimulation in Patients With Advanced Heart Failure: A Randomized Invasive Clinical Trial , 2022, Circulation. Heart failure.

[8]  M. Ko,et al.  Loss of adipose TET proteins enhances β-adrenergic responses and protects against obesity by epigenetic regulation of β3-AR expression , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[9]  G. Semenza,et al.  Hypoxia-inducible factors: cancer progression and clinical translation , 2022, The Journal of clinical investigation.

[10]  Paul N. Mudd Jr,et al.  Selectivity and Maximum Response of Vibegron and Mirabegron for β3-Adrenergic Receptors , 2022, Current therapeutic research, clinical and experimental.

[11]  R. Chess-Williams,et al.  Mirabegron attenuates porcine ureteral contractility via α1-adrenoceptor antagonism , 2022, Naunyn-Schmiedeberg's Archives of Pharmacology.

[12]  Guanfang Su,et al.  Neurovascular abnormalities in retinopathy of prematurity and emerging therapies , 2022, Journal of Molecular Medicine.

[13]  O. Nureki,et al.  Cryo-EM structures of the β3 adrenergic receptor bound to solabegron and isoproterenol. , 2022, Biochemical and biophysical research communications.

[14]  P. Bagnoli,et al.  HIF-1-Dependent Induction of β3 Adrenoceptor: Evidence from the Mouse Retina , 2022, Cells.

[15]  M. Nasr-Esfahani,et al.  Characterization of The Retinal Progenitor Cells Generated Using Co-Culture Systems , 2022, Cell journal.

[16]  A. Pini,et al.  Decoupling Oxygen Tension From Retinal Vascularization as a New Perspective for Management of Retinopathy of Prematurity. New Opportunities From β-adrenoceptors , 2022, Frontiers in Pharmacology.

[17]  M. Chiang,et al.  Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF) , 2021, Progress in Retinal and Eye Research.

[18]  Andrew C. Weitz,et al.  Blocking Ocular Sympathetic Activity Inhibits Choroidal Neovascularization , 2022, Frontiers in Neuroscience.

[19]  A. Pini,et al.  β3‐Adrenoceptor, a novel player in the round‐trip from neonatal diseases to cancer: Suggestive clues from embryo , 2021, Medicinal research reviews.

[20]  M. Campbell,et al.  The blood–retina barrier in health and disease , 2021, The FEBS journal.

[21]  K. Tsubota,et al.  Retinal Diseases Regulated by Hypoxia—Basic and Clinical Perspectives: A Comprehensive Review , 2021, Journal of clinical medicine.

[22]  M. Michel,et al.  Validation of Fenoterol to Study β2-Adrenoceptor Function in the Rat Urinary Bladder , 2021, Pharmacology.

[23]  F. Schena,et al.  β3 adrenergic receptor as potential therapeutic target in ADPKD , 2021, Physiological reports.

[24]  O. How,et al.  The β3 Adrenergic Receptor Antagonist L-748,337 Attenuates Dobutamine-Induced Cardiac Inefficiency While Preserving Inotropy in Anesthetized Pigs , 2021, Journal of cardiovascular pharmacology and therapeutics.

[25]  Jing Dong,et al.  The Association of Trp64Arg Polymorphism in the Beta-Adrenergic Receptor With Insulin Resistance: Meta-Analysis , 2021, Frontiers in Endocrinology.

[26]  A. Zanesco,et al.  The effects of mirabegron on obesity‐induced inflammation and insulin resistance are associated with brown adipose tissue activation but not beiging in the subcutaneous white adipose tissue , 2021, Clinical and experimental pharmacology & physiology.

[27]  O. Nureki,et al.  Cryo-EM structure of the β3-adrenergic receptor reveals the molecular basis of subtype selectivity. , 2021, Molecular cell.

[28]  F. Aslan,et al.  Evaluation of the Effect of a Novel β3-Adrenergic Agonist on Choroidal Vascularity , 2021, Investigative ophthalmology & visual science.

[29]  F. Luo,et al.  β3-adrenoceptor activation exhibits a dual effect on behaviors and glutamate receptor function in the prefrontal cortex , 2021, Behavioural Brain Research.

[30]  C. Sorenson,et al.  Hypoxic–ischemic injury causes functional and structural neurovascular degeneration in the juvenile mouse retina , 2021, Scientific Reports.

[31]  Y. Tseng,et al.  β3-Adrenergic receptors regulate human brown/beige adipocyte lipolysis and thermogenesis , 2021, JCI insight.

[32]  F. Calon,et al.  Repurposing beta-3 adrenergic receptor agonists for Alzheimer’s disease: beneficial effects in a mouse model , 2021, Alzheimer's research & therapy.

[33]  S. Mohammad,et al.  Functional Characterization of the Obesity-Linked Variant of the β3-Adrenergic Receptor , 2021, International journal of molecular sciences.

[34]  A. Caporali,et al.  Autophagy at the interface of endothelial cell homeostasis and vascular disease , 2021, The FEBS journal.

[35]  G. Figtree,et al.  β 3 Adrenergic Receptor Stimulation Promotes Reperfusion in Ischemic Limbs in a Murine Diabetic Model , 2021, Frontiers in Pharmacology.

[36]  T. Kurihara,et al.  HIF Inhibition Therapy in Ocular Diseases. , 2021, The Keio journal of medicine.

[37]  V. Prokosch,et al.  Energy Metabolism in the Inner Retina in Health and Glaucoma , 2021, International journal of molecular sciences.

[38]  C. Shawber,et al.  Propranolol Therapy in Infantile Hemangioma: It Is Not Just About the Beta , 2021, Plastic and reconstructive surgery.

[39]  E. Chang,et al.  80 Years of vision: preventing blindness from retinopathy of prematurity , 2021, Journal of Perinatology.

[40]  A. Pini,et al.  Infantile hemangiomas β3-adrenoceptor overexpression is associated with nonresponse to propranolol , 2021, Pediatric Research.

[41]  Qin Zhou,et al.  Clinical Efficacy and Safety of Propranolol in the Prevention and Treatment of Retinopathy of Prematurity: A Meta-Analysis of Randomized Controlled Trials , 2021, Frontiers in Pediatrics.

[42]  A. Yazdanyar,et al.  Animal models of diabetic retinopathy , 2021, Annals of translational medicine.

[43]  F. Britton,et al.  Effect of β1/β2‐adrenoceptor blockade on β3‐adrenoceptor activity in the rat cremaster muscle artery , 2021, British journal of pharmacology.

[44]  Yue Ruan,et al.  The Role of Adrenoceptors in the Retina , 2020, Cells.

[45]  J. Balligand,et al.  The Beta3 Adrenergic Receptor in Healthy and Pathological Cardiovascular Tissues , 2020, Cells.

[46]  P. Bagnoli,et al.  Novel Insights into Beta 2 Adrenergic Receptor Function in the rd10 Model of Retinitis Pigmentosa , 2020, Cells.

[47]  B. Kobilka,et al.  Analysis of β2AR-Gs and β2AR-Gi complex formation by NMR spectroscopy , 2020, Proceedings of the National Academy of Sciences.

[48]  P. R. Somanath,et al.  Regulation of blood-retinal barrier cell-junctions in diabetic retinopathy. , 2020, Pharmacological research.

[49]  Yifei Huang,et al.  Inhibition of retinal neovascularization by VEGF siRNA delivered via bioreducible lipid-like nanoparticles , 2020, Graefe's Archive for Clinical and Experimental Ophthalmology.

[50]  B. Bui,et al.  Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[51]  F. Tempia,et al.  Role of β3‐adrenergic receptor in the modulation of synaptic transmission and plasticity in mouse cerebellar cortex , 2020, Journal of neuroscience research.

[52]  Yue Yuan,et al.  Hypoxia-inducible factor-1α: A promising therapeutic target for vasculopathy in diabetic retinopathy. , 2020, Pharmacological research.

[53]  Yuxian He,et al.  The Trp64Arg polymorphism in β3 adrenergic receptor (ADRB3) gene is associated with adipokines and plasma lipids: a systematic review, meta-analysis, and meta-regression , 2020, Lipids in Health and Disease.

[54]  J. Balligand,et al.  Beta 3 adrenoreceptors protect from hypertrophic remodelling through AMP‐activated protein kinase and autophagy , 2020, ESC heart failure.

[55]  R. E. El Khouli,et al.  The β3-adrenergic receptor agonist mirabegron improves glucose homeostasis in obese humans. , 2020, The Journal of clinical investigation.

[56]  Jiali Cheng,et al.  β3 adrenergic receptor antagonist SR59230A exerts beneficial effects on right ventricular performance in monocrotaline-induced pulmonary arterial hypertension , 2019, Experimental and therapeutic medicine.

[57]  M. Campbell,et al.  Tight Junctions of the Outer Blood Retina Barrier , 2019, International journal of molecular sciences.

[58]  M. Dal Monte,et al.  Upregulation of β3-adrenoceptors—a general marker of and protective mechanism against hypoxia? , 2019, Naunyn-Schmiedeberg's Archives of Pharmacology.

[59]  H. Perlman,et al.  Monocyte-Derived Macrophages Are Necessary for Beta-Adrenergic Receptor-Driven Choroidal Neovascularization Inhibition , 2019, Investigative ophthalmology & visual science.

[60]  David J. Wilson,et al.  Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. , 2019, Ophthalmology.

[61]  S. Angers,et al.  Agonist‐induced desensitisation of β3‐adrenoceptors: Where, when, and how? , 2019, British journal of pharmacology.

[62]  M. Michel,et al.  Cardiac β3‐adrenoceptors—A role in human pathophysiology? , 2019, British journal of pharmacology.

[63]  G. Semenza,et al.  HIF-1α is required for development of the sympathetic nervous system , 2019, Proceedings of the National Academy of Sciences.

[64]  G. Buonocore,et al.  Propranolol 0.2% Eye Micro-Drops for Retinopathy of Prematurity: A Prospective Phase IIB Study , 2019, Front. Pediatr..

[65]  N. Ferrara,et al.  VEGF in Signaling and Disease: Beyond Discovery and Development , 2019, Cell.

[66]  N. Marrion,et al.  β3-Adrenergic receptor-dependent modulation of the medium afterhyperpolarization in rat hippocampal CA1 pyramidal neurons. , 2019, Journal of neurophysiology.

[67]  A. Iolascon,et al.  HIF-1 transcription activity: HIF1A driven response in normoxia and in hypoxia , 2019, BMC medical genetics.

[68]  B. Rini,et al.  HIF Inhibitors: Status of Current Clinical Development , 2019, Current Oncology Reports.

[69]  P. Westgate,et al.  Human adipose beiging in response to cold and mirabegron. , 2018, JCI insight.

[70]  C. Villalón,et al.  β-Adrenoceptor Blockade for Infantile Hemangioma Therapy: Do β3-Adrenoceptors Play a Role? , 2018, Journal of Vascular Research.

[71]  J. Luna,et al.  A journey into the retina: Müller glia commanding survival and death , 2018, The European journal of neuroscience.

[72]  R. Rodrigo,et al.  HIF‐1α stabilization reduces retinal degeneration in a mouse model of retinitis pigmentosa , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[73]  Marcus Fruttiger,et al.  Retinal vasculature development in health and disease , 2017, Progress in Retinal and Eye Research.

[74]  P. Bagnoli,et al.  Potential role of the methylation of VEGF gene promoter in response to hypoxia in oxygen‐induced retinopathy: beneficial effect of the absence of AQP4 , 2017, Journal of cellular and molecular medicine.

[75]  P. Bagnoli,et al.  The Beta Adrenergic Receptor Blocker Propranolol Counteracts Retinal Dysfunction in a Mouse Model of Oxygen Induced Retinopathy: Restoring the Balance between Apoptosis and Autophagy , 2017, Front. Cell. Neurosci..

[76]  Lois E. H. Smith,et al.  Endothelial adenosine A2a receptor-mediated glycolysis is essential for pathological retinal angiogenesis , 2017, Nature Communications.

[77]  G. Buonocore,et al.  Study protocol: safety and efficacy of propranolol 0.2% eye drops in newborns with a precocious stage of retinopathy of prematurity (DROP-ROP-0.2%): a multicenter, open-label, single arm, phase II trial , 2017, BMC Pediatrics.

[78]  L. Køber,et al.  The first‐in‐man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the BEAT‐HF trial , 2017, European journal of heart failure.

[79]  S. Kurtoğlu,et al.  The Efficacy of Propranolol in Retinopathy of Prematurity and its Correlation with the Platelet Mass Index , 2017, Current eye research.

[80]  G. Stark,et al.  Hypoxia sensing through β-adrenergic receptors. , 2016, JCI insight.

[81]  M. Mastrodonato,et al.  β3 adrenergic receptor in the kidney may be a new player in sympathetic regulation of renal function , 2016, Kidney international.

[82]  C. Lazcano,et al.  Oral propranolol in early stages of retinopathy of prematurity , 2016, Journal of perinatal medicine.

[83]  Y. Liu,et al.  Critical Roles of STAT3 in &bgr;-Adrenergic Functions in the Heart , 2016, Circulation.

[84]  R. Danesi,et al.  Pathophysiology and pharmacological targets of VEGF in diabetic macular edema. , 2016, Pharmacological research.

[85]  Grazia Maugeri,et al.  PACAP Modulates Expression of Hypoxia-Inducible Factors in Streptozotocin-Induced Diabetic Rat Retina , 2015, Journal of Molecular Neuroscience.

[86]  T. Angelone,et al.  β3‐AR and the vertebrate heart: a comparative view , 2015, Acta physiologica.

[87]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[88]  E. Giannoni,et al.  Norepinephrine promotes tumor microenvironment reactivity through β3-adrenoreceptors during melanoma progression , 2014, Oncotarget.

[89]  M. Michel,et al.  The Odd Sibling: Features of β3-Adrenoceptor Pharmacology , 2014, Molecular Pharmacology.

[90]  P. Bagnoli,et al.  The β-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases , 2014, Progress in Retinal and Eye Research.

[91]  J. Espinosa,et al.  Transcriptional regulation by hypoxia inducible factors , 2014, Critical reviews in biochemistry and molecular biology.

[92]  P. Bagnoli,et al.  Protective effects of β1/2 adrenergic receptor deletion in a model of oxygen-induced retinopathy. , 2014, Investigative ophthalmology & visual science.

[93]  S. Houser,et al.  Chronic β1-adrenergic blockade enhances myocardial β3-adrenergic coupling with nitric oxide-cGMP signaling in a canine model of chronic volume overload: new insight into mechanisms of cardiac benefit with selective β1-blocker therapy , 2014, Basic Research in Cardiology.

[94]  S. Furlanetto,et al.  Oral propranolol for retinopathy of prematurity: risks, safety concerns, and perspectives. , 2013, The Journal of pediatrics.

[95]  M. Michel,et al.  The new radioligand [(3)H]-L 748,337 differentially labels human and rat β3-adrenoceptors. , 2013, European journal of pharmacology.

[96]  O. Dammann,et al.  Retinopathy of prematurity , 2013, The Lancet.

[97]  G. Semenza,et al.  Hypoxic retinal Müller cells promote vascular permeability by HIF-1–dependent up-regulation of angiopoietin-like 4 , 2013, Proceedings of the National Academy of Sciences.

[98]  P. Bagnoli,et al.  Functional involvement of β3-adrenergic receptors in melanoma growth and vascularization , 2013, Journal of Molecular Medicine.

[99]  A. Mitra,et al.  Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases. , 2013, Current drug targets.

[100]  C. Garrido,et al.  Biphasic Erk1/2 activation sequentially involving Gs and Gi signaling is required in beta3-adrenergic receptor-induced primary smooth muscle cell proliferation. , 2013, Biochimica et biophysica acta.

[101]  S. Blazer,et al.  Oral propranolol versus placebo for retinopathy of prematurity: a pilot, randomised, double-blind prospective study , 2013, Archives of Disease in Childhood.

[102]  N. Sheibani,et al.  Attenuation of choroidal neovascularization by β(2)-adrenoreceptor antagonism. , 2013, JAMA ophthalmology.

[103]  F. Mosca,et al.  Propranolol concentrations after oral administration in term and preterm neonates , 2013, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[104]  M. Michel,et al.  β3-Adrenoceptors: a drug target in ophthalmology? , 2013, Naunyn-Schmiedeberg's Archives of Pharmacology.

[105]  M. Sasamata,et al.  In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats , 2013, Naunyn-Schmiedeberg's Archives of Pharmacology.

[106]  P. Bagnoli,et al.  Beta3-adrenergic receptors modulate vascular endothelial growth factor release in response to hypoxia through the nitric oxide pathway in mouse retinal explants , 2013, Naunyn-Schmiedeberg's Archives of Pharmacology.

[107]  P. Bagnoli,et al.  Different efficacy of propranolol in mice with oxygen-induced retinopathy: could differential effects of propranolol be related to differences in mouse strains? , 2012, Investigative ophthalmology & visual science.

[108]  A. Mori,et al.  Protective effects of the β3-adrenoceptor agonist CL316243 against N-methyl-D-aspartate-induced retinal neurotoxicity , 2012, Naunyn-Schmiedeberg's Archives of Pharmacology.

[109]  W. Lamers,et al.  Specificity evaluation of antibodies against human β3-adrenoceptors , 2012, Naunyn-Schmiedeberg's Archives of Pharmacology.

[110]  Lois E. H. Smith,et al.  Propranolol inhibition of β-adrenergic receptor does not suppress pathologic neovascularization in oxygen-induced retinopathy. , 2012, Investigative ophthalmology & visual science.

[111]  P. Bagnoli,et al.  Beta-adrenoreceptor agonism influences retinal responses to hypoxia in a model of retinopathy of prematurity. , 2012, Investigative ophthalmology & visual science.

[112]  H. Okano,et al.  The formation of an angiogenic astrocyte template is regulated by the neuroretina in a HIF-1-dependent manner. , 2012, Developmental biology.

[113]  P. Bagnoli,et al.  Antiangiogenic effects of β2‐adrenergic receptor blockade in a mouse model of oxygen‐induced retinopathy , 2011, Journal of neurochemistry.

[114]  Jeroen A. A. Demmers,et al.  VEGFR2 Translocates to the Nucleus to Regulate Its Own Transcription , 2011, PloS one.

[115]  A. Mori,et al.  Role of β3-adrenoceptors in regulation of retinal vascular tone in rats , 2011, Naunyn-Schmiedeberg's Archives of Pharmacology.

[116]  Jiannis Ragoussis,et al.  High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. , 2011, Blood.

[117]  Lena Claesson-Welsh,et al.  Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. , 2011, Molecular aspects of medicine.

[118]  R. Summers,et al.  Role of β‐adrenoceptors in glucose uptake in astrocytes using β‐adrenoceptor knockout mice , 2011, British journal of pharmacology.

[119]  P. Fortunato,et al.  Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. , 2011, Investigative ophthalmology & visual science.

[120]  P. Ochodnický,et al.  Tissue functions mediated by β3-adrenoceptors—findings and challenges , 2010, Naunyn-Schmiedeberg's Archives of Pharmacology.

[121]  Jing Chen,et al.  The mouse retina as an angiogenesis model. , 2010, Investigative ophthalmology & visual science.

[122]  I. Cantuti-Castelvetri,et al.  Hypoxia Inducible Factor-1α (HIF-1α) and Some HIF-1 Target Genes are Elevated in Experimental Glaucoma , 2010, Journal of Molecular Neuroscience.

[123]  P. V. van Diest,et al.  Active HIF-1 in the Normal Human Retina , 2010, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[124]  P. Sagot,et al.  SAR150640, a selective β3‐adrenoceptor agonist, prevents human myometrial remodelling and activation of matrix metalloproteinase in an in vitro model of chorioamnionitis , 2010, British journal of pharmacology.

[125]  B. A. Evans,et al.  Ligand‐directed signalling at β‐adrenoceptors , 2010, British journal of pharmacology.

[126]  A. Scilimati,et al.  β(3)-Adrenoceptor agonists and (antagonists as) inverse agonists history, perspective, constitutive activity, and stereospecific binding. , 2010, Methods in enzymology.

[127]  J. Rivera,et al.  Proliferative retinopathies: angiogenesis that blinds. , 2010, The international journal of biochemistry & cell biology.

[128]  Y. Le,et al.  Müller cell‐derived VEGF is a significant contributor to retinal neovascularization , 2009, The Journal of pathology.

[129]  W. Franklin,et al.  Adenosine A2A receptor is a unique angiogenic target of HIF-2α in pulmonary endothelial cells , 2009, Proceedings of the National Academy of Sciences.

[130]  T. Kern,et al.  Increased basement membrane thickness, pericyte ghosts, and loss of retinal thickness and cells in dopamine beta hydroxylase knockout mice. , 2009, Experimental eye research.

[131]  P. Schaaf,et al.  O2 Level Controls Hematopoietic Circulating Progenitor Cells Differentiation into Endothelial or Smooth Muscle Cells , 2009, PloS one.

[132]  E. Raschi,et al.  The beta3-adrenoceptor as a therapeutic target: current perspectives. , 2009, Pharmacological research.

[133]  E. Ling,et al.  Blood–retinal barrier in hypoxic ischaemic conditions: Basic concepts, clinical features and management , 2008, Progress in Retinal and Eye Research.

[134]  Y. Claustre,et al.  Effects of the β3-adrenoceptor (Adrb3) agonist SR58611A (amibegron) on serotonergic and noradrenergic transmission in the rodent: Relevance to its antidepressant/anxiolytic-like profile , 2008, Neuroscience.

[135]  R. Walker,et al.  Role of β-Adrenergic Receptors in Inflammatory Marker Expression in Müller Cells , 2007 .

[136]  N. Aiyar,et al.  GW427353 (Solabegron), a Novel, Selective β3-Adrenergic Receptor Agonist, Evokes Bladder Relaxation and Increases Micturition Reflex Threshold in the Dog , 2007, Journal of Pharmacology and Experimental Therapeutics.

[137]  Enrica Strettoi,et al.  Retinal organization in the retinal degeneration 10 (rd10) mutant mouse: A morphological and ERG study , 2007, The Journal of comparative neurology.

[138]  M. Michel,et al.  Tools to study β3-adrenoceptors , 2007, Naunyn-Schmiedeberg's Archives of Pharmacology.

[139]  Naresh Kumar,et al.  Maximal β3-Adrenergic Regulation of Lipolysis Involves Src and Epidermal Growth Factor Receptor-dependent ERK1/2 Activation* , 2006, Journal of Biological Chemistry.

[140]  B. Turgut,et al.  Relaxant effects of beta-adrenoceptor agonist formoterol and BRL 37344 on bovine iris sphincter and ciliary muscle. , 2006, European journal of pharmacology.

[141]  R. Verrier.  Beta3-adrenoceptor: friend or foe? , 2005, Heart rhythm.

[142]  R. Sidman,et al.  Spare the rod and spoil the eye , 2005, British Journal of Ophthalmology.

[143]  H. Granger,et al.  Beta 3-adrenergic receptors mediate choroidal endothelial cell invasion, proliferation, and cell elongation. , 2005, Experimental eye research.

[144]  M. Wax,et al.  Hypoxia-inducible factor 1α in the glaucomatous retina and optic nerve head , 2004 .

[145]  J. Balligand,et al.  Endothelial &bgr;3-Adrenoceptors Mediate Vasorelaxation of Human Coronary Microarteries Through Nitric Oxide and Endothelium-Dependent Hyperpolarization , 2004, Circulation.

[146]  Martin J. Lohse,et al.  What Is the Role of &bgr;-Adrenergic Signaling in Heart Failure? , 2003, Circulation research.

[147]  H. Granger,et al.  β3-Adrenergic Receptors Regulate Retinal Endothelial Cell Migration and Proliferation* , 2003, Journal of Biological Chemistry.

[148]  E. V. Famiglietti,et al.  Immunocytochemical localization of vascular endothelial growth factor in neurons and glial cells of human retina , 2003, Brain Research.

[149]  K. Klotz,et al.  Comparative pharmacology of human β-adrenergic receptor subtypes—characterization of stably transfected receptors in CHO cells , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

[150]  O. Yamaguchi.  β3-adrenoceptors in human detrusor muscle ☆ , 2002 .

[151]  M. T. Davisson,et al.  Retinal degeneration mutants in the mouse , 2002, Vision Research.

[152]  Michael I. Wilson,et al.  C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation , 2001, Cell.

[153]  J. Balligand,et al.  Upregulation of &bgr;3-Adrenoceptors and Altered Contractile Response to Inotropic Amines in Human Failing Myocardium , 2001, Circulation.

[154]  T. Chan-Ling,et al.  Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis. , 2000, Investigative ophthalmology & visual science.

[155]  P. Campochiaro,et al.  Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. , 1999, Investigative ophthalmology & visual science.

[156]  Y. Oron,et al.  β3‐Adrenergic relaxation of bovine iris sphincter , 1998 .

[157]  J L Benovic,et al.  Role of Clathrin-mediated Endocytosis in Agonist-induced Down-regulation of the β2-Adrenergic Receptor* , 1998, The Journal of Biological Chemistry.

[158]  L. Bukowiecki,et al.  Role of β1- and β3-adrenoceptors in the regulation of lipolysis and thermogenesis in rat brown adipocytes. , 1997, American journal of physiology. Cell physiology.

[159]  James C. Scott,et al.  Gene expression of catecholamine synthesizing enzymes and β adrenoceptor subtypes during rat embryogenesis , 1997, Neuroscience Letters.

[160]  S. Bhattacharya,et al.  An essential role for p300/CBP in the cellular response to hypoxia. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[161]  A. Strosberg,et al.  Function and regulation of the 3-adrenoceptor , 1996 .

[162]  B. Lowell,et al.  Targeted Disruption of the β3-Adrenergic Receptor Gene * , 1995, The Journal of Biological Chemistry.

[163]  D. Fox,et al.  Oxygen consumption in the rat outer and inner retina: light- and pharmacologically-induced inhibition. , 1995, Experimental eye research.

[164]  Lois E. H. Smith,et al.  Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[165]  G. Semenza,et al.  Purification and Characterization of Hypoxia-inducible Factor 1 (*) , 1995, The Journal of Biological Chemistry.

[166]  P. Mauriège,et al.  Characterization of β1‐ and β3‐adrenoceptors in intact brown adipocytes of the rat , 1995 .

[167]  Lois E. H. Smith,et al.  Oxygen-induced retinopathy in the mouse. , 1994, Investigative ophthalmology & visual science.

[168]  A. Strosberg,et al.  The human beta 3-adrenergic receptor is resistant to short term agonist-promoted desensitization. , 1993, Molecular pharmacology.

[169]  A. Strosberg,et al.  Molecular characterization of the human beta 3-adrenergic receptor. , 1989, Science.

[170]  J. Palacios,et al.  Autoradiographic localization of high affinity GABA, benzodiazepine, dopaminergic, adrenergic and muscarinic cholinergic receptors in the rat, monkey and human retina , 1986, Brain Research.

[171]  N. Osborne,et al.  The presence of dopamine-β-hydroxylase-like enzyme in the vertebrate retina , 1985, Neurochemistry International.

[172]  N. Osborne.  Noradrenaline, a Transmitter Candidate in the Retina , 1981, Journal of neurochemistry.

[173]  H. Saltzman,et al.  RETINAL OXYGEN UTILIZATION MEASURED BY HYPERBARIC BLACKOUT. , 1964, Archives of ophthalmology.